Pharmacological aspects of antituberculous drugs

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptdepartment of pharmacology and pharmacotherapy.hu_HU
dc.contributor.authorMatta, Johan
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentDrimba, László
dc.contributor.opponentSzentmiklósi, József András
dc.contributor.opponentdeptKenézy Kórház Központi Aneszteziológiai és Intezív Terápiás Osztályhu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.date.accessioned2020-02-04T12:40:03Z
dc.date.available2020-02-04T12:40:03Z
dc.date.created2019-09-27
dc.description.abstractTuberculosis disease is a life-threatening disease, the second most common infectious disease leading to death worldwide after HIV. An early diagnosis and treatment of active tuberculosis disease and LTBI, is important to prevent the spreading of the bacteria and protection of the individual health. First-line antituberculous drugs rifampin, isoniazid, ethambutol and pyrazinamide are highly effective against tuberculosis, given for 6 months period. Patient should persist in taking the drug daily without interruption, because therapy interruption can lead to development of drugs resistant tuberculosis strains, which would be harder to treat.hu_HU
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent50hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/280321
dc.language.isoenhu_HU
dc.subjectantituberculous drugshu_HU
dc.subject.dspaceDEENK Témalista::Orvostudományhu_HU
dc.titlePharmacological aspects of antituberculous drugshu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)